A small Seat­tle biotech wants to take on Glax­o­SmithK­line's emerg­ing Shin­grix block­buster. RA Cap­i­tal is on board

Glax­o­SmithK­line’s Shin­grix has quick­ly be­come one of the com­pa­ny’s best-sell­ing prod­ucts since first win­ning FDA ap­proval in 2017. But a new biotech be­lieves it can do bet­ter — and RA Cap­i­tal is lis­ten­ing.

Cure­vo Vac­cine, a Seat­tle-based com­pa­ny, de­buted a $60 mil­lion Se­ries A on Thurs­day led by the promi­nent life sci­ences VC, aim­ing to fund a Phase IIb study for its shin­gles vac­cine can­di­date. The pro­gram, known as CRV-101, will be mea­sured against Shin­grix as the con­trol and pits the two shots head-to-head.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER